Leveraging single-cell RNA-seq for uncovering naïve B cells associated with better prognosis of hepatocellular carcinoma

Abstract

Hepatocellular carcinoma (HCC) is a typical highly heterogeneous solid tumor with high morbidity and mortality worldwide, especially in China; however, the immune microenvironment of HCC has not been clarified so far. Here, we employed single-cell RNA sequencing (scRNA-seq) on diethylnitrosamine (DEN)-induced mouse HCC model to dissect the immune cell dynamics during tumorigenesis. Our findings reveal distinct immune profiles in both precancerous and cancerous lesions, indicating early tumor-associated immunological alterations. Notably, specific T and B cell subpopulations are preferentially enriched in the HCC tumor microenvironment (TME). Furthermore, we identified a subpopulation of naïve B cells with high CD83 expression, correlating with improved prognosis in human HCC. These signature genes were validated in The Cancer Genome Atlas HCC RNA-seq dataset. Moreover, cell interaction analysis revealed that subpopulations of B cells in both mouse and human samples are activated and may potentially contribute to oncogenic processes. In summary, our study provides insights into the dynamic immune microenvironment and cellular networks in HCC pathogenesis, with a specific emphasis on naïve B cells. These findings emphasize the significance of targeting TME in HCC patients to prevent HCC pathological progression, which may give a new perspective on the therapeutics for HCC.

Keywords

B cell / diethylnitrosamine / hepatocellular carcinoma / prognosis / single-cell sequencing / transcriptomics

References

[1] Luoma AM, Suo S, Williams HL, et al. Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell. 2020; 182(3): 655-671. e22.

[2] He J, Lin F, Yang X, Wang D, Tan X, Zhang S. Sustainable synthesis of 2-arylbenzoxazoles over a cobalt-based nanocomposite catalyst. Org Process Res Dev. 2016; 20(6): 1093-1096.

[3] Kieffer Y, Hocine HR, Gentric G, et al. Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer. Cancer Discov. 2020; 10(9): 1330-1351.

[4] Zheng H, Peng X, Yang S, et al. Targeting tumor-associated macrophages in hepatocellular carcinoma: biology, strategy, and immunotherapy. Cell Death Discov. 2023; 9(1): 65.

[5] Kurt FGO, Lasser S, Arkhypov I, Utikal J, Umansky V. Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target. J Clin Invest. 2023; 133(13): e170762.

[6] Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022; 77(6): 1598-1606.

[7] He J, Meng M, Wang H. A novel prognostic biomarker LPAR6 in hepatocellular carcinoma via associating with immune infiltrates. J Clin Transl Hepatol. 2022; 10(1): 90-103.

[8] Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2015; 12(12): 681-700.

[9] Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016; 16(5): 275-287.

[10] De Strooper B, Karran E. The cellular phase of Alzheimer’s disease. Cell. 2016; 164(4): 603-615.

[11] Habib N, Avraham-Davidi I, Basu A, et al. Massively parallel single-nucleus RNA-seq with DroNc-seq. Nat Methods. 2017; 14(10): 955-958.

[12] He J, Meng M, Zhou X, Gao R, Wang H. Isolation of single cells from human hepatoblastoma tissues for whole-exome sequencing. STAR Protoc. 2023; 4(1): 102052.

[13] Tirosh I, Izar B, Prakadan SM, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016; 352(6282): 189-196.

[14] Liu Y, Xun Z, Ma K, et al. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J Hepatol. 2023; 78(4): 770-782.

[15] He J, Lin YX, Meng M, Li JQ, Yang JYH, Wang H. Construction of a human cell landscape of COVID-19 infection at single-cell level. Aging Dis. 2021; 12(3): 705-709.

[16] Zhou X, Meng M, Wu Y, et al. Protocol to dissociate and isolate wide-diversity single cells by density gradient centrifugation from human hepatoblastoma tissue. STAR Protoc. 2023; 4(3): 102449.

[17] Seehawer M, Heinzmann F, D’artista L, et al. Necroptosis microenvironment directs lineage commitment in liver cancer. Nature. 2018; 562(7725): 69-75.

[18] Zhang Q, He Y, Luo N, et al. Landscape and dynamics of single immune cells in hepatocellular carcinoma. Cell. 2019; 179(4): 829-845. e20.

[19] Sun Y, Wu L, Zhong Y, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell. 2021; 184(2): 404-421. e16.

[20] Sharma A, Seow JJW, Dutertre CA, et al. Onco-fetal reprogramming of endothelial cells drives immunosuppressive macrophages in hepatocellular carcinoma. Cell. 2020; 183(2): 377-394. e21.

[21] Yu J, Green MD, Li S, et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat Med. 2021; 27(1): 152-164.

[22] Xue R, Zhang Q, Cao Q, et al. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. Nature. 2022; 612(7938): 141-147.

[23] Filliol A, Saito Y, Nair A, et al. Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis. Nature. 2022; 610(7931): 356-365.

[24] Aizarani N, Saviano A, Sagar , et al. A human liver cell atlas reveals heterogeneity and epithelial progenitors. Nature. 2019; 572(7768): 199-204.

[25] Zhang W, Zhangyuan G, Wang F, et al. The zinc finger protein Miz1 suppresses liver tumorigenesis by restricting hepatocyte-driven macrophage activation and inflammation. Immunity. 2021; 54(6): 1168-1185. e8.

[26] Li Z, Zhou Y, Jia K, et al. JMJD4-demethylated RIG-I prevents hepatic steatosis and carcinogenesis. J Hematol Oncol. 2022; 15(1): 1-19.

[27] Vesselinovitch S, Koka M, Mihailovich N, Rao K. Carcinogenicity of diethylnitrosamine in newborn, infant, and adult mice. J Cancer Res Clin Oncol. 1984; 108(1): 60-65.

[28] Cheng J, Zhong Y, Chen S, et al. Gab2 mediates hepatocellular carcinogenesis by integrating multiple signaling pathways. FASEB J. 2017; 31(12): 5530.

[29] Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol. 2018; 36(5): 411-420.

[30] Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013; 13(4): 227-242.

[31] Kurioka A, Walker LJ, Klenerman P, Willberg CB. MAIT cells: new guardians of the liver. Clin Transl Immunol. 2016; 5(8): e98.

[32] Böttcher JP, Beyer M, Meissner F, et al. Functional classification of memory CD8+ T cells by CX3CR1 expression. Nat Commun. 2015; 6(1): 8306.

[33] Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009; 114(8): 1537-1544.

[34] Daud AI, Loo K, Pauli ML, et al. Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma. J Clin Invest. 2016; 126(9): 3447-3452.

[35] Li J, Wu C, Hu H, et al. Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer. Cancer Cell. 2023; 41(6): 1152-1169.

[36] Wang X, Zha H, Wu W, et al. CD200+ cytotoxic T lymphocytes in the tumor microenvironment are crucial for efficacious anti–PD-1/PD-L1 therapy. Sci Transl Med. 2023; 15(679): eabn5029.

[37] Vento-Tormo R, Efremova M, Botting RA, et al. Single-cell reconstruction of the early maternal–fetal interface in humans. Nature. 2018; 563(7731): 347-353.

[38] Förster R, Davalos-Misslitz AC, Rot A. CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol. 2008; 8(5): 362-371.

[39] Wang S-S, Liu W, Ly D, Xu H, Qu L, Zhang L. Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer. Cell Mol Immunol. 2019; 16(1): 6-18.

[40] Khedr OMS, El-Sonbaty SM, Moawed FSM, Kandil EI, Abdel-Maksoud BE. Lactobacillus acidophilus ATCC 4356 exopolysaccharides suppresses mediators of inflammation through the inhibition of TLR2/STAT-3/P38-MAPK pathway in DEN-induced hepatocarcinogenesis in rats. Nutr Cancer. 2022; 74(3): 1037-1047.

[41] Liu YZ, Xu QS, Deng F, et al. HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway. J Exp Clin Cancer Res. 2023; 42(1): 38.

[42] Mirlekar B, Wang Y, Li SR, et al. Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity. Cell Rep Med. 2022; 3(9): 100744.

[43] Iglesia MD, Vincent BG, Parker JS, et al. Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. Clin Cancer Res. 2014; 20(14): 3818-3829.

[44] Lundberg A, Li B, Li R. B cell-related gene signature and cancer immunotherapy response. Br J Cancer. 2022; 126(6): 899-906.

[45] Tsou P, Katayama H, Ostrin EJ, Hanash SM. The emerging role of B cells in tumor immunity. Cancer Res. 2016; 76(19): 5597-5601.

[46] Lohr M, Edlund K, Botling J, et al. The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer. Cancer Lett. 2013; 333(2): 222-228.

[47] Mahmoud S, Lee A, Paish E, Macmillan R, Ellis I, Green A. The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat. 2012; 132: 545-553.

[48] Wei Y, Huang C-X, Xiao X, et al. B cell heterogeneity, plasticity, and functional diversity in cancer microenvironments. Oncogene. 2021; 40(29): 4737-4745.

[49] Bai L, Chen W, Chen J, et al. Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application. J Transl Med. 2017; 15(1): 1-10.

[50] Martin F, Chan AC. B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol. 2006; 24: 467-496.

[51] Stoycheva D, Simsek H, Weber W, Hauser AE, Klotzsch E. External cues to drive B cell function towards immunotherapy. Acta Biomater. 2021; 133: 222-230.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.